“A Phase II International, Multicenter Study of Oral Panobinostat (LBH589) in Patients With Refractory Cutaneous T-Cell Lymphoma”. Hematology Meeting Reports 2, no. 5 (June 23, 2009). Accessed April 18, 2026. https://journals.pagepress.net/hmr/article/view/725.